Gilead and Arcellx presented pivotal-stage data for anito‑cel showing deep, durable responses in multiple myeloma, positioning the CAR‑T product as a potential best‑in‑class therapy ahead of a planned launch. STAT and ASH briefings reported high overall and complete response rates with an encouraging safety profile in the analyzed cohort, and Gilead executives described commercial readiness plans. The readout underscores competition in multiple myeloma cell therapy and the ongoing industry push to expand access and manufacturing scale. CAR‑T therapies remain capital- and infrastructure-intensive; Gilead is investing in manufacturing and reimbursement strategies to support broader uptake if anito‑cel secures approval.